JY
NPCE icon

Jeff Yass’s Neuropace NPCE Stock Holding History

Jeff Yass’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-16,300
Closed -$182K – 13419
2025
Q2 		$182K Buy
+16,300
New +$204K ﹤0.01% 11307

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Jeff Yass's NPCE Position: Q2 2026 in Review

Jeff Yass reduced its Neuropace (NPCE) stake by 60% in Q2 2026, selling an estimated $242K and leaving 10,154 shares worth $161K. The position accounts for ﹤0.01% of the portfolio, ranked #12147.

Jeff Yass first reported a position in NPCE in Q1 2023 and has held it in 9 quarters since. The position peaked at $2.69M in Q1 2024. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Jeff Yass held 10,154 shares of Neuropace worth $161K as of Q2 2026.
  • Jeff Yass sold 15,026 Neuropace shares in Q2 2026, an estimated $242K.
  • Neuropace made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12147 holding.
  • Jeff Yass first reported a position in Neuropace in Q1 2023 and has held it in 9 quarters since.
  • Jeff Yass's Neuropace position peaked at $2.69M in Q1 2024.
  • 112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.